Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405879 | 1.00 | KMT2A (0.58) | KMT2AMEN1ALDH1A1MAPTLMNA | |
| SCHEMBL2400630 | 0.98 | KMT2A (0.61) | KMT2AMEN1ALDH1A1MAPTLMNA | |
| SCHEMBL2400636 | 0.98 | KMT2A (0.61) | KMT2AMEN1ALDH1A1MAPTLMNA | |
| SCHEMBL2401122 | 0.89 | ALDH1A1 (0.50) | KMT2AMEN1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL2401119 | 0.89 | ALDH1A1 (0.50) | KMT2AMEN1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL27750512 | 0.88 | ALDH1A1 (0.57) | KMT2AMEN1ALDH1A1LMNATSHR | |
| SCHEMBL2404164 | 0.88 | ALDH1A1 (0.57) | KMT2AMEN1ALDH1A1LMNATSHR | |
| SCHEMBL2402205 | 0.87 | ALDH1A1 (0.50) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2402209 | 0.87 | ALDH1A1 (0.50) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2402269 | 0.84 | HRH3 (0.53) | KMT2AMEN1ALDH1A1THRBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017773-B2 | Cyclohexyl sulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-1979322-B1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-20100120791-A1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES | NETTEKOVEN MATTHIAS | 2010-05-13 | — | — | US | disclosed |
| EP-1979322-A1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007082840-A1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES HAVING H3 RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173511-A1 | Cyclohexyl sulfonamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120791-A1 | CYCLOHEXYL SULFONAMIDE DERIVATIVES | HRH3, HRH4, HRH1 | KMT2A 338/4885MEN1 3462/4885ALDH1A1 430/4885 |
| US-20070173511-A1 | Cyclohexyl sulfonamide derivatives | HRH3, HRH4, HRH1 | KMT2A 338/4885MEN1 3462/4885ALDH1A1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.